Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04288726 · ClinicalTrials.gov registry record · Phase 1
Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas
A Phase 1 study of Classical Hodgkin Lymphoma and Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type, sponsored by Baylor College of Medicine.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
- 2
- Study locations
NCT04288726 is a Phase 1 study of Classical Hodgkin Lymphoma and Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type that is actively recruiting participants, run by Baylor College of Medicine. The registered enrollment target is 18 participants, below the 77-participant average among 8 other Classical Hodgkin Lymphoma trials with a reported enrollment target (77% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT04288726, a Phase 1 study of Classical Hodgkin Lymphoma and Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type, is actively recruiting participants, sponsored by Baylor College of Medicine.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study involved patients that have a cancer called diffuse large B cell lymphoma (DLBCL), NK and T cell lymphomas (NK/TL) or classical Hodgkin lymphoma (cHL) (hereafter these 3 diseases will be referred to as lymphoma). Patients lymphoma has come back or not gone away after treatment. Because there is no standard treatment for the patients cancer at this time or because the currently used treatments do not work fully in all cases, the patients are being asked to volunteer in this research study. In this study the investigators want to test a type of T cell made from a normal donor. The T cells the investigators will use are called Epstein Barr virus (EBV) specific T cells (EBVSTs) and are cells that the investigators have trained in the laboratory to recognize a EBV which is the virus that causes mono or kissing disease. Some patients with lymphoma have EBV in their cancer cells. Researchers have given T cell lines from normal donor EBVSTs to lymphoma patients who have EBV in their lymphoma cells and have seen responses in about half the patients. The cells have have been generated and are frozen in a bank. The cells are called "allogeneic" (meaning the donor is not related to the patient). CD30.CAR in EBV-specific T cells (called allogeneic CD30.CAR-EBVST) from the blood of healthy donors. The investigators are giving the cells to patients with lymphoma cells that express CD30. If the lymphoma cells also express EBV there may be some benefit from targeting both proteins. The purpose of this study is to find out the highest safe dose of allogeneic CD30.CAR-EBVST cells given following chemotherapy and used to treat lymphoma. The investigators will learn the side effects of CD30.CAR-EBVST cells in patients and see whether this therapy may help lymphoma patients
Conditions Studied
Interventions
- BIOLOGICAL CD30.CAR-EBVST cells
Study Locations (2)
Texas
- Houston Methodist Hospital - Houston
- Texas Children's Hospital - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2020-09-16 |
| Est. Completion | 2037-06-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04288726
The ClinicalTrials.gov registry entry for NCT04288726 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 77-participant average among 8 other Classical Hodgkin Lymphoma trials with a reported enrollment target (77% lower). The listed sponsor is Baylor College of Medicine, which has 616 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Classical Hodgkin Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which CD30.CAR-EBVST cells is the first listed.
NCT04288726 reports 2 study locations spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT04288726 about?
NCT04288726 is a clinical study titled "Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas". This study involved patients that have a cancer called diffuse large B cell lymphoma (DLBCL), NK and T cell lymphomas (NK/TL) or classical Hodgkin lymphoma (cHL) (hereafter these 3 diseases will be referred to as lymphoma). Patients lymphoma has come back or not gone away after treatment. Because th...
What is the current status of trial NCT04288726?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2020-09-16. Estimated completion is 2037-06-01.
What conditions does trial NCT04288726 study?
This clinical trial studies the following conditions: Classical Hodgkin Lymphoma, Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type.
What interventions are being tested in trial NCT04288726?
The interventions under investigation include: CD30.CAR-EBVST cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT04288726?
This trial is sponsored by Baylor College of Medicine, which has 616 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04288726 being conducted?
This trial has 2 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Classical Hodgkin Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies
RECRUITING · Phase 1
-
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
RECRUITING · Phase 1
-
Autologous CD30.CAR-T in Combination With Nivolumab in cHL Patients After Failure of Frontline Therapy
ACTIVE NOT RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers
ACTIVE NOT RECRUITING · Phase 1
-
Itacitinib + Everolimus in Hodgkin Lymphoma
ACTIVE NOT RECRUITING · Phase 1
-
Phase Ib of L-NMMA and Pembrolizumab
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Classical Hodgkin Lymphoma
All registered trials for this condition
Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type
All registered trials for this condition
Texas
All trials with a study site in Texas
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.